Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  title={Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.},
  author={Kadoaki Ohashi and Yosef E. Maruvka and Franziska Michor and William Pao},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={31 8},
PURPOSE EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. METHODS This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. RESULTS The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
140 Citations
112 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 140 extracted citations


Publications referenced by this paper.
Showing 1-10 of 112 references

AstraZeneca Pharmaceuticals LP: Withdrawal of approval of a new drug Application for IRESSA

  • J Woodcock
  • Federal Register 77:24723-24724,
  • 2012
Highly Influential
9 Excerpts

AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

  • VM Rivera, F Wang, R Anjum
  • Cancer Res 72, 2012
  • 1794
Highly Influential
5 Excerpts

CO1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations

  • AO Walter, R Tjin, H Haringsma
  • Mol Cancer Ther
  • 2011
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…